One treatment in particular drove pharmaceutical sales growth in 2015
A report by US pharmaceutical industry news website First World Pharma has listed the 50 fastest selling drug brands in 2015.
Between them the 50 products generated combined year-on-year growth of US$41 billion.
One single product – Gilead Sciences’ hepatitis C treatment Harvoni – accounted for 29 percent of this figure, with incremental growth of US$11.7 billion (A$15.2 billion).
Harvoni (sofosbuvir + ledipasvir) is one of the new direct-acting antiviral medications listed on the PBS from 1 March 2016.
There are still unresolved issues relating to the cost to pharmacies of stocking and supplying these medicines, as reported by AJP.
Eleven of the products delivered incremental growth in excess of A$1 billion (eight in excess of US$1 billion) in 2015, three of which were also hepatitis C drugs.
In fourth place is the world’s top selling pharmaceutical brand, arthritis treatment Humira (Adalimumab), with overall sales of US$14 billion (A$18.3 billion), up by US$1.4 billion.
Multiple myeloma treatment Revlimid came in eleventh, with 2015 sales growth of US$821 million (just over A$1bn).
The top 11 also included anticoagulant Eliquis and age-related macular degeneration treatment Eylea.
Click here to see the full-list of the 50 fastest growing brands in 2015.
The top 20 (in US$) are:
|Prevnar||Pfizer||Streptococcus pneumoniae (vaccine)||1781|
|Eylea||Regeneron||Age-related macular degeneration||940|